The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Genomic evolution of patients with CLL who progress on pirtobrutinib in the BRUIN trial
Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, comments on the genomic evolution in patients with chronic lymphocytic leukemia (CLL) previously exposed to covalent BTK inhibitor (BTKi) treatment who progressed on pirtobrutinib monotherapy in the BRUIN trial (NCT03740529). Using targeted sequencing of 74 genes, the most common mutations identified at baseline were in BTK. At progression, the majority of mutations were either non-BTK or not in the target panel, suggesting that alternative resistance mechanisms are responsible. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Loxo/Lilly, Pharmacyclics, Numab Therapeutics, Merck, Grifols Worldwide Operations, Kite, BeiGene, iOnctura, Alloplex Biotherapeutics, Hutchmed, Pfizer, Genentech/Roche, Abbvie, Acerta/AstraZeneca; Research Funding: Loxo/Lilly, TG Therapeutics, Gilead, BeiGene, iOnctura, SecuraBio, MEI Pharma.
